- Home
- ANAB vs NGL Comparison
ANAB vs NGL Comparison
Compare ANAB & NGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- NGL
- Stock Information
- Founded
- ANAB 2005
- NGL 1940
- Country
- ANAB United States
- NGL United States
- Employees
- ANAB N/A
- NGL N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- NGL Natural Gas Distribution
- Sector
- ANAB Health Care
- NGL Utilities
- Exchange
- ANAB Nasdaq
- NGL Nasdaq
- Market Cap
- ANAB 759.5M
- NGL 645.5M
- IPO Year
- ANAB 2017
- NGL 2011
- Fundamental
- Price
- ANAB $18.59
- NGL $4.79
- Analyst Decision
- ANAB Buy
- NGL
- Analyst Count
- ANAB 12
- NGL 0
- Target Price
- ANAB $41.20
- NGL N/A
- AVG Volume (30 Days)
- ANAB 1.4M
- NGL 620.9K
- Earning Date
- ANAB 03-10-2025
- NGL 02-10-2025
- Dividend Yield
- ANAB N/A
- NGL N/A
- EPS Growth
- ANAB N/A
- NGL N/A
- EPS
- ANAB N/A
- NGL N/A
- Revenue
- ANAB $57,172,000.00
- NGL $5,918,601,000.00
- Revenue This Year
- ANAB $229.13
- NGL N/A
- Revenue Next Year
- ANAB N/A
- NGL N/A
- P/E Ratio
- ANAB N/A
- NGL N/A
- Revenue Growth
- ANAB 282.17
- NGL N/A
- 52 Week Low
- ANAB $12.21
- NGL $3.84
- 52 Week High
- ANAB $41.31
- NGL $6.20
- Technical
- Relative Strength Index (RSI)
- ANAB 55.28
- NGL 43.51
- Support Level
- ANAB $12.21
- NGL $4.21
- Resistance Level
- ANAB $21.57
- NGL $5.08
- Average True Range (ATR)
- ANAB 1.72
- NGL 0.27
- MACD
- ANAB 0.39
- NGL -0.06
- Stochastic Oscillator
- ANAB 68.16
- NGL 38.16
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About NGL NGL ENERGY PARTNERS LP Common Units representing Limited Partner Interests
NGL Energy Partners LP is a USA-based firm that owns and operates a vertically integrated energy business. The company's operating segments include Crude Oil Logistics, Water Solutions, and Liquids Logistics. It operates crude oil Logistics, owns pipeline injection stations, and offers services for the treatment and disposal of wastewater generated from crude oil and natural gas production, and for the disposal of solids, such as tank bottoms and drilling fluids. The firm also supplies natural gas liquids to retailers, wholesalers, refiners, and petrochemical plants and sells propane and distillates.